Revolution Medicines Inc (RVMD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $37.27B
Last updated: Nov 17, 2026 at 11:06 AM ET
Revolution Medicines Inc (RVMD) Competitors
The companies most similar to Revolution Medicines are Roivant Sciences (ROIV), Insmed (INSM) and Royalty Pharma Plc (RPRX). By market cap, Revolution Medicines ranks 5th of the 13 companies on this page; Moderna (MRNA) is the largest at $90.38B. The median P/E of the 6 companies with a P/E is 34.7x.
Peer Comparison
RVMD's ROIC of -52.1% is below the peer median of 4.8%, and its revenue growth of -95.2% is below the median of 43.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | $37.27B | N/A | 181.6x | 0.0% | -52.1% | -95.2% | 0.00% |
| Roivant Sciences Ltd (ROIV) | $28.64B | N/A | 679.3x | 0.0% | N/A | 2136.0% | 0.00% |
| Insmed Inc (INSM) | $26.58B | N/A | 17.7x | -39.9% | -44.2% | 268.4% | 0.00% |
| Royalty Pharma Plc (RPRX) | $39.85B | 12.9x | 11.7x | 25.7% | 7.6% | 13.3% | 1.37% |
| Exelixis Inc (EXEL) | $16.84B | 19.3x | 6.9x | 35.4% | N/A | 10.2% | 0.00% |
| BeOne Medicines AG (ONC) | $47.58B | 50.0x | 18.7x | 13.9% | 7.5% | 33.8% | 0.00% |
| Genmab AS (GMAB) | $31.67B | 35.8x | 19.2x | 17.0% | 4.8% | 16.1% | 0.00% |
| argenx NV ADR (ARGX) | $60.37B | 33.5x | 6.1x | 31.7% | N/A | 52.1% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Moderna Inc (MRNA) | $90.38B | N/A | 34.2x | -110.5% | -28.9% | 29.2% | 0.00% |
| Ascendis Pharma AS (ASND) | $18.06B | N/A | 13.5x | 72.9% | 12.4% | 73.0% | 0.00% |
| Praxis Precision Medicines Inc (PRAX) | $9.17B | N/A | N/A | 0.0% | N/A | 1349.0% | 0.00% |
| Krystal Biotech Inc (KRYS) | $9.05B | 40.4x | 18.8x | 47.9% | N/A | 30.2% | 0.00% |
| Peer median | $27.61B | 34.7x | 17.7x | 15.4% | 4.8% | 43.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Revolution Medicines, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Roivant Sciences Ltd (ROIV) | Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive... | ROIV competitors |
| Insmed Inc (INSM) | Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. | INSM competitors |
| Royalty Pharma Plc (RPRX) | Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. | RPRX competitors |
| Exelixis Inc (EXEL) | Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development... | EXEL competitors |
| BeOne Medicines AG (ONC) | BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe... | ONC competitors |
| Genmab AS (GMAB) | Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark. | GMAB competitors |
| argenx NV ADR (ARGX) | argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases... | ARGX competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
| Moderna Inc (MRNA) | Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology... | MRNA competitors |
| Ascendis Pharma AS (ASND) | Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark. | ASND competitors |
| Praxis Precision Medicines Inc (PRAX) | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal... | PRAX competitors |
| Krystal Biotech Inc (KRYS) | Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United... | KRYS competitors |
Frequently Asked Questions About RVMD
Who are Revolution Medicines' main competitors?
The companies most similar to Revolution Medicines include Roivant Sciences (ROIV), Insmed (INSM), Royalty Pharma Plc (RPRX), Exelixis (EXEL) and BeOne Medicines AG (ONC), listed from the closest match.
Who is Revolution Medicines' biggest competitor?
Moderna (MRNA) is the largest of the similar companies at $90.38B; Roivant Sciences (ROIV) is the closest match by business profile, size, sector and industry.
How does RVMD stock compare with its competitors?
RVMD's P/S is 181.6x against a peer median of 17.7x; its net margin is 0.0% against a peer median of 15.4%.
Which of Revolution Medicines' competitors pays a higher dividend?
Revolution Medicines pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.
Is Revolution Medicines bigger than its competitors?
No. Revolution Medicines is 5th by market cap among the 13 companies on this page; the largest is Moderna (MRNA) at $90.38B.
RVMD pages: Overview, Earnings, Forecast, Financials, Competitors